Floatz logo

ETOPOSIDE

Adebrelimab

Fujian Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Adebrelimab cohort.

Asset / SponsorPhaseRating
Adebrelimab
Fujian Cancer Hospital
Phase 2CCC
Vunakizumab
Fujian Cancer Hospital
Phase 2CCC
Carboplatin
Fujian Cancer Hospital
Phase 2CCC
Rivoceranib
The First Affiliated Hospital of Xiamen University
Phase 2CCC

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →